14.2.2024 07:30:01 CET | Thor Medical ASA | Inside information

The Board of Thor Medical ASA has today engaged Mr. Jasper Kurth (39) as the
company's next Chief Executive Officer.

Mr. Kurth joins Thor Medical from several positions at Bayer Pharmaceuticals,
most recently as General Manager Radiology Nordics in Stockholm. Prior to that,
Mr. Kurth held the following positions at Bayer Pharmaceuticals: Head of
Business Operations & Strategy EMEA, Head of Sub-Region Western Europe Radiology
(acting), and Chief of Staff and Head of Training Radiology Europe. Mr. Kurth
has been with Bayer Pharmaceuticals since he joined Bayer's Management Trainee
Program as a young student. Mr. Kurth will join Thor Medical no later than
September 1.

When Mr. Kurth assumes the position as Chief Executive Officer, Dr. Alf Bjørseth
(82), will continue to support the company's client acquisition and technical
development of a production facility for thorium-based alpha emitters at Herøya,
Norway as Senior Vice President & Strategic Advisor.

Ludvik Sandnes, Chairman of the Board, says: We are very pleased that we have
been able to attract Jasper Kurth to lead our team and further development of
our company. At Bayer Pharmaceuticals, he has obtained an outstanding experience
which we are very grateful that he will now share with us. 

Jasper Kurth comments: Joining Thor Medical fills me with immense excitement and
anticipation. I am thrilled to be part of a team dedicated to revolutionizing
healthcare and making a tangible difference in the lives of patients battling
cancer. Together, we'll push boundaries, innovate relentlessly, and forge a
brighter future in the fight against this devastating disease.

The Board of Thor Medical has resolved to award Jasper Kurth 3 600 000 share
options. Each share option entitles Mr. Kurth to buy one share at NOK 1.118,
equal to the volume-weighted share price over the last ten trading days. 1/3 of
the share options will vest 12 months after Mr. Kurth's first day of employment,
while the remaining share options will vest with 100 000 on the last day of each
month following the initial vesting. The share options need to be exercised no
later than five years after the initial award. The total gross benefit for
exercised share options under this award shall be limited to Mr. Kurth's total
base salary of the three-year period. The award of share options is made subject
to the approval of the company's General Meeting.



A notification of the transaction in accordance with the EU Market Abuse
Regulation article 19 is attached with this announcement.



DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Ludvik Sandnes, Chairman of the Board, +47 907 43 017 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2914/4078/Download%20announcement
%20as%20PDF.pdf

Thor Medical Primary insider notification CEO.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2914/4076/Thor%20Medical%20Primar
y%20insider%20notification%20CEO.pdf